Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis

Manuel Valladares-Ayerbes, Pilar García Alfonso, Volker Heinemann, Paolo Manca, Sebastian Stintzing, Filipo Pietrantonio, Clara Montagut, Maria José Safont Aguilera, Joan Maurel, Encarna González Flores, Joana Vidal, Vincenzo Formica, Montse Sabaté-Pina, Verónica Alfonso-González, Gerard Prat-Llorens

Open source

DOI: 10.21037/jgo-2025-1-879
Published: 2026-08
Container: Journal of Gastrointestinal Oncology
Publisher: AME Publishing Company
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21037/jgo-2025-1-879,
  title = {Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis},
  author = {Manuel Valladares-Ayerbes and Pilar García Alfonso and Volker Heinemann and Paolo Manca and Sebastian Stintzing and Filipo Pietrantonio and Clara Montagut and Maria José Safont Aguilera and Joan Maurel and Encarna González Flores and Joana Vidal and Vincenzo Formica and Montse Sabaté-Pina and Verónica Alfonso-González and Gerard Prat-Llorens},
  year = {2026},
  journal = {Journal of Gastrointestinal Oncology},
  doi = {10.21037/jgo-2025-1-879},
  url = {https://doi.org/10.21037/jgo-2025-1-879}
}

RIS

TY  - JOUR
TI  - Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis
AU  - Manuel Valladares-Ayerbes
AU  - Pilar García Alfonso
AU  - Volker Heinemann
AU  - Paolo Manca
AU  - Sebastian Stintzing
AU  - Filipo Pietrantonio
AU  - Clara Montagut
AU  - Maria José Safont Aguilera
AU  - Joan Maurel
AU  - Encarna González Flores
AU  - Joana Vidal
AU  - Vincenzo Formica
AU  - Montse Sabaté-Pina
AU  - Verónica Alfonso-González
AU  - Gerard Prat-Llorens
PY  - 2026
JO  - Journal of Gastrointestinal Oncology
DO  - 10.21037/jgo-2025-1-879
UR  - https://doi.org/10.21037/jgo-2025-1-879
ER  -

APA

Valladares-Ayerbes, M., Alfonso, P. G., Heinemann, V., Manca, P., Stintzing, S., Pietrantonio, F., Montagut, C., Aguilera, M. J. S., Maurel, J., Flores, E. G., Vidal, J., Formica, V., Sabaté-Pina, M., Alfonso-González, V., & Prat-Llorens, G. (2026). Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis. Journal of Gastrointestinal Oncology. https://doi.org/10.21037/jgo-2025-1-879

Source records

crossref · retrieved 2026-09-26T11:43:43.876Z